If you're thinking about having a baby, the health of the sperm is important. We all know that a nutritious diet, a healthy weight, avoiding smoking and alcohol, and attention to other preventive factors can increase your chance of having a baby. But sometimes this isn't enough. It takes two to make a baby, and having healthy sperm is one of the important factors in getting pregnant.
Scientists think that antioxidants and other nutrients may be able to help protect sperm from damage, and keep them healthy and on the move. Our researchers at NICM are looking for men to volunteer for a clinical study which will test the effects of a nutritional supplement on sperm health.
Pre-evaluated for safety and permitted for inclusion in oral medicines in Australia, Hominax is listed as a medicine with the Australian Register of Therapeutic Goods and approved for use by the Australian Therapeutic Goods Administration.
Recruitment is now underway in City Fertility clinics located at Brisbane, Brisbane Southside and the Gold Coast; the Royal Hospital for Women, Randwick Sydney and Parramatta.
You will be enrolled in the study to receive the nutritional supplement for 24 weeks. The estimated time commitment is four hours over six months, and travel reimbursements of up to $125 per visit are available. You will be asked to provide four semen samples for analysis, and to have two blood tests over the six months.
Eligibility and more information
If you have been told your sperm health could be better, you might be eligible for this study. You do not need to be actively trying to conceive to volunteer for the study.
In order to register your interest and confirm your eligibility, please see survey below.
Sperm Health Study Survey (opens in a new window)
For more information please contact NICM Research Officer, Afshan Khan
p. (02) 4620 3810
m. 0414 357 363
For health information about maximising your fertility, visit yourfertility.org.au (opens in a new window)
Read the participant information sheet (opens in a new window)
This clinical trial has been approved by Western Sydney University Human Research Ethics Committee (Approval Number: H11411) and is supported by NICM, Western Sydney University and Max Biocare Pty. Ltd.